2 Reasons the FDA Is Likely to Authorize the Johnson & Johnson Vaccine Next Week

2 Reasons the FDA Is Likely to Authorize the Johnson & Johnson Vaccine Next Week
Adria Cimino, The Motley Fool
·4 min read

Johnson & Johnson's (NYSE: JNJ) big moment is right around the corner. A U.S. Food and Drug Administration (FDA) committee meets on Friday to advise on a possible Emergency Use Authorization (EUA) for the company's coronavirus vaccine candidate. The FDA already granted EUAs for vaccines to two companies: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).